BrainsWay Expands Market Reach with $5M Investment in Neurolief

BrainsWay, a neurostimulation treatment leader, has invested $5 million in Neurolief Ltd. to expand its market reach into home-administered mental health treatments. Neurolief's Proliv™Rx device, pending FDA approval, would be the first FDA-cleared treatment for Major Depressive Disorder for home use. The investment includes up to $11 million in milestone-based funding and a call option for future acquisition. This strategic move aims to broaden market access and address treatment gaps for mental health disorders.

Neurolief Ltd., a pioneering neuromodulation company, has received a strategic investment of $5 million from BrainsWay Ltd., a global leader in non-invasive neurostimulation therapies. This investment marks a significant milestone for Neurolief as it prepares for the commercial launch of its Proliv™Rx device, designed to treat Major Depressive Disorder (MDD) at home. The funding includes up to $11 million in milestone-based funding and a call option for future acquisition, reflecting BrainsWay's strategic expansion into the at-home mental health treatment market [1].

The Proliv™Rx device, currently pending FDA approval, represents a paradigm shift in depression treatment. If approved, it would be the first FDA-cleared treatment for MDD that can be administered outside clinical settings. Neurolief's technology is a wearable, non-invasive, multi-channel brain neuromodulation system designed for home use, offering a practical and effective alternative to traditional treatments [2].

The partnership between BrainsWay and Neurolief aims to address the critical gap in mental health care for patients who do not respond adequately to traditional treatments. Major Depressive Disorder remains one of the most prevalent and burdensome mental health conditions worldwide, with a significant subset of patients failing to respond to traditional treatments such as antidepressant medications [3]. The Proliv™Rx device offers a non-invasive brain stimulation therapy that can be administered at home, potentially reducing healthcare costs and improving patient access to effective treatment.

The investment also reflects BrainsWay's commitment to expanding its market reach and addressing treatment gaps for mental health disorders. BrainsWay's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform is FDA-cleared for three indications: major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction [3]. The $5 million investment in Neurolief strategically expands BrainsWay's market reach into the at-home neuromodulation market for mental health disorders, with significant growth potential.

Neurolief's Proliv™Rx device, if approved, would significantly enhance the accessibility and effectiveness of mental health treatments. The device's at-home administration would allow patients to receive treatment in a comfortable and convenient environment, potentially improving patient compliance and outcomes. Additionally, the device's non-invasive nature could reduce the risk of side effects associated with traditional treatments.

In conclusion, BrainsWay's investment in Neurolief represents a strategic move to expand its market reach into the at-home mental health treatment market. The partnership aims to address treatment gaps for Major Depressive Disorder and improve patient access to effective mental health treatments. The successful development and commercialization of the Proliv™Rx device could significantly impact the mental health treatment landscape and improve the lives of millions of patients worldwide.

References:

[1] https://theoutpost.ai/news-story/ai-set-to-revolutionize-mental-health-care-for-breast-cancer-patients-19389/
[2] https://finance.yahoo.com/news/neurolief-prepares-launch-proliv-rx-133200092.html
[3] https://www.stocktitan.net/news/BWAY/brains-way-targets-expansion-of-its-total-addressable-market-through-4ystqobjeljl.html